Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD cut its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 34.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 638,964 shares of the biopharmaceutical company's stock after selling 338,432 shares during the period. Price T Rowe Associates Inc. MD owned 0.41% of Ocular Therapeutix worth $5,458,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new stake in shares of Ocular Therapeutix in the fourth quarter valued at about $1,722,000. Charles Schwab Investment Management Inc. boosted its holdings in Ocular Therapeutix by 1.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company's stock worth $9,663,000 after buying an additional 21,025 shares during the last quarter. Barclays PLC increased its stake in Ocular Therapeutix by 37.1% during the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock worth $4,451,000 after buying an additional 138,441 shares in the last quarter. RoundAngle Advisors LLC acquired a new position in shares of Ocular Therapeutix during the fourth quarter valued at approximately $1,695,000. Finally, Rosalind Advisors Inc. lifted its position in shares of Ocular Therapeutix by 27.5% in the fourth quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company's stock valued at $9,639,000 after acquiring an additional 243,700 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on OCUL shares. William Blair began coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They set an "outperform" rating on the stock. Royal Bank of Canada started coverage on shares of Ocular Therapeutix in a report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price objective on the stock. JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Needham & Company LLC decreased their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday. Finally, HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Ocular Therapeutix has a consensus rating of "Moderate Buy" and a consensus target price of $16.25.

Insider Activity at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,475 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the transaction, the insider now directly owns 3,520,318 shares of the company's stock, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.50% of the stock is owned by corporate insiders.

Ocular Therapeutix Stock Down 1.8 %

Shares of NASDAQ:OCUL traded down $0.13 during trading on Wednesday, hitting $7.05. The company's stock had a trading volume of 1,985,608 shares, compared to its average volume of 1,428,752. The company has a market capitalization of $1.12 billion, a PE ratio of -5.34 and a beta of 1.51. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. Ocular Therapeutix, Inc. has a fifty-two week low of $4.79 and a fifty-two week high of $11.78. The business has a 50 day moving average price of $7.42 and a two-hundred day moving average price of $8.35.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The company had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. As a group, research analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.